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LETTER
Engineering vascularized skeletal muscle
tissue with transcriptional factor ETV2-induced
autologous endothelial cells
Dear Editor,
Newly engineered tissues often fail to function due to
insufficient blood vessels formation. Autologous vascular
endothelial cells are ideal sources for tissue engineering but
are often of limited availability. We first identified that tran-
scriptional factor Etv2 (ets variant 2, initially named as Etsrp)
was specifically expressed in the zebrafish vascular
endothelial cells and was required for vascular development
in zebrafish (Sumanas and Lin, 2006). ETV2 has been found
to increase endothelial differentiation of human and mouse
embryonic stem cells as well as to directly transdifferentiate
somatic cells into endothelial-like cells (Lindgren et al., 2015;
Morita et al., 2015). In zebrafish embryos, overexpression of
Etv2/Etsrp induced vascular gene expression and converted
fast skeletal muscle cells into endothelial cells that were
incorporated in functional blood vessels (Veldman et al.,
2013). This finding suggests that ETV2 could be potentially
used to generate autologous endothelial cells from human
skeletal muscle cells for regenerative medicine. It is worth
noting that protocols for skeletal muscle cells isolation and
ex vivo expansion have been well established, allowing
efficient production of muscle satellite cells/myoblasts from
minimally tissue invasive (Webster et al., 1988). Therefore,
selection of skeletal muscle cells as an alternative isogenic
source for generating endothelial cells has practical advan-
tages and benefits.
In this study we compared capacity of several human cell
types to be induced to express endothelial genes by ETV2
and showed that human skeletal muscle cells (HSkMCs) are
highly amendable for this endothelial induction. We first
detected the potential of endothelial transdifferentiation
induced by ETV2 overexpression in five human cell types.
Cells used in this experiment were human skeletal muscle
cells (HSkMCs), adipose-derived mesenchymal stem cells
(ADMSCs), umbilical cord-derived mesenchymal stem cells
(UCMSCs), human embryonic lung fibroblast cells (HFL-1)
and human skin fibroblast cells (HSFs). All these cells were
infected with equal numbers of ETV2 lentivirus. Following
ETV2 lentivirus infection, cell morphologies and expression
of endothelial specific genes were analyzed. The infected
cells all appeared to change morphologies into an
endothelial-like shape. Among them, ETV2-HSkMCs
showed the most uniform conversion, similar to the mor-
phology of human umbilical vein endothelial cells (HUVECs)
(Fig. 1A). Again using HUVECs as a control, the expression
of endothelial cell markers was measured. Flow cytometry
(FCM) analysis revealed that more than 50% of ADMSCs,
UCMSCs, HFL-1, HAFs and HSkMCs expressed endothelial
gene marker CDH5/VE-cadherin/CD144. Surprisingly, under
the same condition, over 90% of HSkMCs were converted to
express CDH5. Similar to CDH5, VEGFR-2 positive popu-
lation were significantly induced after ETV2 expression,
with the highest efficiency in HSkMCs (Figs. 1B and S1).
Based on the findings above and early evidences in
zebrafish we hypothesized that the HSkMCs can be a good
resource for endothelial transdifferentiation. First, the time
course of CDH5 induction by ETV2 was investigated. Flow
cytometry showed that over half of the cells already
expressed CDH5 at 1 day post infection (dpi) and about 90%
at 3 dpi (Fig. 1C). Under the same condition, ETV2-ADMSCs
transdifferent more slowly and less efficient in responding to
ETV2, only about 50% expressed CDH5 at 3 dpi (Fig. S2).
The relatively fast response of HSkMCs to endothelial
induction by ETV2 can be a benefit for the use of this cell
type in regenerative medicine. We then expanded molecular
analysis of endothelial transdifferentiation induced by ETV2.
By qRT-PCR, we confirmed that overexpression of ETV2
induced expression of multiple vascular genes, including
KDR, TAL1, PECAM1 and TEK (Fig. 1D). ETV2-HSkMCs
showed partial positive of CD34, which is similar to HUVECs
(Fig. S3). Next, we tested the ability of HSkMCs to form
vascular tubes in vitro with or without ETV2 expression. The
results showed that ETV2-HSkMCs formed vascular-like
tubes with similar size and structure of HUVECs. Although
HSkMCs alone also formed fiber-like structures, they
appeared different from that of HUVECs (Fig. 1E). Tube
formation assay demonstrates that ETV2 initiates morpho-
logical changes resembling endothelial process in vitro. As
another functional test, we assayed the level of LDL uptake
in these cells. As shown in Figure 1F, after 3 dpi, ETV2-
HSkMCs had acquired the ability to take up DiI-acetylated
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low-density lipoprotein (DiI-Ac-LDL) similar to the endothelial
cells but this was not detected in HSkMCs.
To evaluate the transcriptome-wide effects of ETV2
expression in HSkMCs, we performed microarray studies on
HSkMCs and ETV2-HSkMCs. Through calculating the rela-
tive gene expression level, we identified 694 transcripts with
over 4-fold changes and 3,897 transcripts with over 2-fold
changes. First, when comparing HSkMCs, ETV2-HSkMCs
and independent various endothelial cells microarray data
(Aranguren et al., 2013), heatmap analyses showed that
ETV2-HSkMCs were closer to endothelial cells than
HSkMCs (Fig. S4). Second, ETV2-HSkMCs showed robust
upregulation of vascular related genes and concomitant
downregulation of muscle related genes than HSkMCs.
Specifically, we selected some endothelial specific genes
based on bioinformatics analysis by Bhasin et al. (2010) and
those up-regulated genes after ETV2 expression is shown
as a heatmap in Fig. 1G. And skeletal muscle functional
genes enriched in several downregulated clusters are shown
in Fig. S5B and S5C. Third, Wikipathway analysis showed
universal changes in VEGF-VEGFR2 and striated muscle
contraction pathway (Figs. 1H and S5A). PI3K/AKT pathway,
another endothelial cell differentiation related pathway, was
also highly induced in ETV2-HSkMCs (Fig. S5D). Overall,
transcriptome analysis suggests that ETV2 induced trans-
differentiation of endothelial cells likely involves activating
the VEGF-VEGFR2 and PI3K/AKT pathways.
This direct trans-differentiated process is different from
induced pluripotent stem cell generation in that there is no
pluripotency stage. The major advantages of the induced
endothelial-like cells described here are simple, fast and
efficient. These highly enriched endothelial-like cells could
be directly used in cell based therapies or tissue engineer-
ing, reducing the risk of contamination from additional cell
purification procedures. Since these endothelial-like cells are
induced in a relatively short window of time, they most likely
represent endothelial cells at early stage. Overall, these
studies suggest that ETV2-HSkMCs are readily converted to
ETV2-induced endothelial-like cells (ETV2-iEC).
Skeletal muscle tissue is highly vascularized and
accounts for approximately 40% of the body mass in human
(Frontera and Ochala, 2015). Muscle defects caused by
traumatic events, diabetic tissue damage or surgical opera-
tion such as tumor removal could result in muscle dysfunc-
tion and physical deformities. The current choices of
treatments are limited and inefficient. One promising thera-
peutic option is to implant pre-vascularized engineering
muscle tissue (Koffler et al., 2011; Levenberg et al., 2005). In
most cases, self-vascularization by host or supplement of
endothelial cells directly harvested from host is not adequate
for tissues of large volumes. Without blood vessel formation,
the newly generated tissues will fail to function due to
insufficiency of oxygen and nutrition supply (Griffith and
Naughton, 2002; Novosel et al., 2011). Thus, artificial
reprogramming of autologous somatic cells into vascular
endothelial cells gives considerable new hope to overcome
this longstanding obstacle.
Thus, we thought muscle tissue could be used as a
complex model to test the ability of our ETV2-iEC in forming
vessels. To determine if ETV2-induced endothelial-like cells
(ETV2-iEC) could contribute to vascularization of engineered
muscle tissue for transplantation, we adopted the proce-
dures shown in Figs. 2A and S6A. Both synthetic matrix and
biological materials were used. Decellularized scaffolds are
produced by removing cellular components and antigenicity
from natural tissue but the procedure lacks standardization
and reproducibility (Badylak et al., 2011; Novosel et al.,
2011). The biological scaffolds we used were from Cavia
porcellus (Guinea pig) skeletal muscle tissue and generated
through detergent perfusion and enzymatic digestion, which
removed all cellular material while maintained the three-di-
mensional networks of collagen and elastic fibers (Fig. S6B
and S6C). Synthetic materials like PLLA (poly-(L-lactic acid))
and PLGA (polylactic-glycolic acid) provide physical support
for cells with highly porous biodegradable structures that are
easy to operate and suitable for large-scale production
(Levenberg et al., 2002; Levenberg et al., 2003). The syn-
thetic scaffolds we used were composed of 50% PLLA and
50% PLGA with an average pore diameter of 250 μm, which
were fabricated through a salt-leaching process (Fig. S7).
Thus we engineered muscle tissue using HSkMCs with/
without ETV2-induced endothelial-like cells on the synthetic
polymer scaffolds or the naturally decellularized muscle
scaffolds through the periods of in vitro culture and in vivo
implantation.
First, the ability of these scaffolds to support tissue growth
in vitro was tested. Approximately 1.5 × 106 cells per scaf-
fold, half were CDH5 positive cells and the rest were skeletal
Figure 1. Analysis of endothelial conversion after ETV2
transduction. (A and B) Comparison of endothelial potential
after ETV2 transduction. (A) Before conversion, these cells had
diverse morphologies. 5 days after ETV2 reprogramming,
cobblestone-like shape similar to HUVECs became apparent.
Scale bar: 100 μm. (B) After ETV2 lentivirus infection, HSkMCs,
ADMSCs, UCMSCs, HFL-1, HSFs expressed endothelial
markers CDH5 and KDR. (C) Temporal expression profile of
endothelial maker CDH5 after ETV2 infection. (D) Expression of
endothelial related genes in HUVECs and HSkMCs induced by
ETV2 at 3 dpi, compared to normal HSkMCs. Fold-change is
expressed in a log10 scale. (E) Tube assay of ETV2-HSkMCs
(3 dpi) compared to HUVECs. Scale bars: 200 μm. (F) After 3
dpi, uptake of a-LDL was detected in ETV2-HSkMCs and
HUVECs, but not in HSkMCs. Scale bars: 50 μm. (G) Previously
reported endothelial specific genes were selected for compar-
ison and ETV2 expression in HSkMCs induced up-regulation of
these genes. (H) Wikipathway analysis of microarray data from
control and ETV2-HSkMCs revealed that 37 out of 50 (75%) of
differentially expressed genes in the VEGF-VEGFR2 pathway
were upregulated, while 13 out of 16 (81%) of differentially
expressed genes in the striated muscle contraction pathway
were downregulated.
ETV2-induced endothelial cells from skeletal muscle LETTER
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muscle cells, were injected into the scaffolds and allowed to
grow under tissue culture condition. After 5 days of culture in
decellularized scaffolds or 7 days of culture in PLLA/PLGA
scaffolds, the status of engineered muscle tissue was ana-
lyzed by sectioning and histological staining. The results
showed that CDH5 positive cells that organized into vessel-
A
nt
i-h
P
E
C
A
M
1
D E
Engineered muscle tissue
15 days after implantation
A
nt
i-h
C
D
H
5
2
VT
E-it n
A
F
A
nt
i-G
FP
A
B
C
Human skeletal 
muscle cells
(HSkMCs)
Expansion
P3-P7
ETV2 lentivirus 
CDH5-
KDR-
CDH5+
KDR+
3 days after 
induction
+HSkMCs Implantation
PLGA/PLLA 
scaffolds
In vitro
 culture
Decellularized 
scaffolds
Or
HG
HSkMCs alone HUVECs with HSkMCs
In
 v
itr
o 
cu
ltu
re
ETV2-iEC with HSkMCs ETV2-iEC with HSkMCs
Engineered muscle tissue with GFP-tagged ETV2-iEC
gniniats
E
&
H
Analysis of ETV2-iEC engineered muscle tissue   
Figure 2. Analysis of engineered muscle tissue with ETV2-iEC on PLLA/PLGA scaffolds. (A) Experimental design for muscle
tissue engineering with ETV2-iEC. (B) Analysis of engineered muscle tissue with ETV2-iEC on PLLA/PLGA scaffolds in vitro. DAB
staining of CDH5 showed vessel-like structure formation after in vitro culture with ETV2-iEC or with HUVECs, while HSkMCs alone
had no staining signal. (C–H) In vivo analysis of engineered muscle on PLLA/PLGA scaffolds. (C) Engineered tissue dissected out
from nude mice 15 days after implantation. (D) H&E staining. (E) Immunostaining against ETV2 traced ETV2 expression. (F) Rabbit
GFP mAb showed that some GFP-ETV2 infected cells were placed around vessels and harbored oval biconcave blood cells in
engineered muscle. By brief eosin staining for one second, red blood cells could be stained as red, distinct from the brown signal of
DAB. Immunostaining against human CDH5 (G) and human PECAM1 (H). Yellow arrows indicate vessel structures and black arrow
indicates blood cells in magnified views. Scale bars: 100 μm.
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like structures were only detectable in the muscle tissue
mixed with ETV2-iEC or HUVECs but not in the cell mass by
HSkMCs alone (Figs. 2B and S6D). This finding suggests
that, similar to HUVECs, ETV2-iEC contributed to vascular
formation when mixed with skeletal muscle cells. More
importantly, if only HSkMCs were seeded in these scaffolds,
the cells did not differentiate into CDH5 positive cells and
form any vessel like structures.
Next, we analyzed vascularization of muscle tissue
engineered with ETV2-iEC in vivo. Blocks of hind leg muscle
of nude mice were surgically removed and replaced with our
engineered tissue in the same position. Fifteen days after
engineered muscle tissue implantation, they were removed
and analyzed histologically (Fig. 2C). H&E staining revealed
that tissue generated by co-injection of HSkMCs and ETV2-
iEC survived in PLLA/PLGA and had formed many vessels
(Fig. 2D). Immunohistochemistry results revealed positive
ETV2 expression abundantly around the vessel, supporting
an inductive role of ETV2 in forming new vessels (Fig. 2E).
ETV2-GFP lentivirus were used to produce GFP-tagged
ETV2-induced endothelial cells for engineered muscle tis-
sue. This confirmed that our ETV2-iEC had contributed to
functional vessels formation which enclosed circulating red
blood cells (Fig. 2F). Immunohistochemistry staining using
human specific anti-CDH5 antibody indicated that these
human CDH5 positive cells were further incorporated into
functional vessels in nude mice with red blood cells inside,
indicating successful blood circulation (Fig. 2G). Similar
results were obtained from tissue grown in decellularized
scaffolds (Fig. S6E and S6F). It seems that the types of
scaffold materials did not significantly affect angiogenesis
induced by ETV2-iEC. Anti-human nuclei antibody staining
confirmed that human cells contributed to the blood vessels
(Fig. S8). Muscle tissue with ETV2-iEC also contained some
human PECAM1 positive cells in the vessel area, indicate
the maturation of these endothelial-like cells (Figs. 2H and
S6G). Thus, we proved that ETV2-iEC contributed to func-
tional blood vessels formation in engineered muscle. This
finding suggests possibility of engineering isogenic vascu-
larized muscle tissue using a single source of patient-
specific skeletal muscle cells.
In conclusion, our studies indicate that ETV2-HSkMCs
contribute to vessel formation in vitro and in vivo, and may
have potential to be developed as an autologous endothelial
cell source for clinical applications.
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